Similarly, empagliflozin, an SGLT-2 inhibitor, has been shown to improve liver steatosis in T2DM patients with NAFLD or nonalcoholic steatohepatitis (NASH) [15–18]. The gene discussed is SLC5A2; the disease is Hepatic steatosis.